Form 4: Amneal Pharmaceuticals Director Sells Over 94,000 Shares Under Pre-Arranged Plan

Amneal Pharmaceuticals, Inc. Director Gautam Patel sold 94,906 shares of Class A Common Stock for approximately $8.02 per share on June 16, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Gautam Patel, a Director of Amneal Pharmaceuticals, Inc. (AMRX), disposed of 94,906 shares of Class A Common Stock.
• The transaction occurred on June 16, 2025.
• The shares were sold at a weighted average price of $8.02 per share, with individual transaction prices ranging from $8.00 to $8.05 per share, inclusive.
• Following this transaction, Mr. Patel beneficially owns 1,609,144 shares of Class A Common Stock directly.
• The sale was executed automatically pursuant to a Rule 10b5-1(c) trading plan, which was adopted by Mr. Patel on August 15, 2024.

Sentiment

Score: 5

Explanation: While an insider sale can be viewed negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates concerns that it's based on new, negative insider information. It's a routine, planned liquidity event.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information, which can mitigate concerns about insider selling.

Negatives

• A director selling a significant number of shares (94,906) could be perceived negatively by investors, as it reduces their direct stake in the company.

Risks

• The primary risk related to this filing is the potential negative market perception of an insider sale, even if pre-planned, which could lead to short-term share price volatility.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The sale of shares by Gautam Patel, a Director, is considered a related party transaction. However, it is a standard open-market sale under a pre-arranged plan.

Stakeholder Impact

• Shareholders: May perceive the sale as a slight negative due to a director reducing their stake, though the 10b5-1 plan context lessens this impact. It provides transparency regarding insider transactions.
• Employees, Customers, Suppliers, Creditors: Unlikely to have a direct impact from this specific insider trading report.

Key Dates

Recommendation

Keywords

Amneal Pharmaceuticals, AMRX, Gautam Patel, Director, Insider Sale, Form 4, SEC Filing, Stock Transaction, Rule 10b5-1, Class A Common Stock